Compensation Disclaimer
VivoSim Inc. (NASDAQ: VIVS) may engage third-party investor relations, marketing, advertising, media, and communications firms to provide investor awareness, research, promotional, and corporate communications services. Any compensation paid for such services may create potential conflicts of interest, including situations in which third-party service providers may own, purchase, or sell securities of VivoSim Inc. at any time.
Nothing contained on this website constitutes investment advice, financial advice, or a recommendation to buy, sell, or hold any security.
All content is provided for informational and educational purposes only.
Introduction
This website provides information and research relating to VivoSim Inc. (NASDAQ: VIVS), including information concerning the Company’s business, technology, human-relevant 3D tissue models, pharmaceutical contract research services, market opportunities, strategic initiatives, financial developments, and future prospects.
Information published on this website may include webpages, research articles, investor-oriented content, company announcements, investor presentations, press releases, newsletters, emails, videos, and other communications (collectively, the “Publications”).
The Publications are intended for general informational and investor-awareness purposes only and should not be relied upon as a substitute for independent research, professional financial advice, or a review of VivoSim’s publicly available regulatory filings and disclosures.
Compensation Disclosure
VivoSim Inc. may compensate third-party marketing agencies, investor relations firms, public relations consultants, media organizations, research publishers, advertising providers, and other service providers for services related to corporate communications, investor awareness, marketing, advertising, research, and promotional activities.
Such compensation may be provided through cash payments, consulting or service agreements, advertising expenditures, sponsorship arrangements, retainers, or other customary business arrangements.
Third-party service providers engaged by or on behalf of VivoSim may have their own interests in the Company’s securities and may purchase, sell, or otherwise transact in VivoSim Inc. securities without notice to the Company or website visitors.
Conflicts of Interest
Investors should be aware that investor-awareness, marketing, research, advertising, and promotional activities may create actual or perceived conflicts of interest.
Third-party service providers involved in the preparation, publication, distribution, or promotion of content relating to VivoSim may hold positions in the Company’s securities and may increase, decrease, or liquidate those positions at any time.
Accordingly, readers should consider the potential for conflicts of interest when evaluating any content published on this website.
Any discussion of VivoSim Inc. (NASDAQ: VIVS), including its technology, NAMkind™ platform, pharmaceutical contract research services, market opportunity, financial performance, commercial prospects, or growth opportunities, should be independently evaluated using publicly available information.
No Investment Advice
The information contained in the Publications is provided for informational purposes only and is not intended to constitute, and should not be construed as, investment advice, financial advice, legal advice, tax advice, or a recommendation to purchase, sell, or hold any security.
Neither this website nor its publisher is acting as a registered investment adviser, broker-dealer, securities analyst, financial planner, or other investment professional solely by providing the information contained in these Publications.
Investors should conduct their own independent due diligence and consult with qualified financial, legal, tax, or investment professionals before making any investment decision concerning VivoSim Inc. (NASDAQ: VIVS) or any other security.
Forward-Looking Statements
Certain information published on this website may contain forward-looking statements concerning VivoSim’s business, technology, commercialization strategy, market opportunities, revenue potential, future growth, regulatory developments, or other anticipated events and results.
Forward-looking statements may include words and expressions such as “may,” “could,” “will,” “expect,” “anticipate,” “intend,” “believe,” “plan,” “estimate,” “potential,” “target,” and similar terminology.
These statements are based on assumptions, expectations, and information available at the time they are made and are subject to risks and uncertainties. Actual results and future developments may differ materially from those expressed or implied by such statements.
Readers should review VivoSim’s official SEC filings and other public disclosures for a discussion of applicable risks and uncertainties.
No Guarantee of Results
Nothing on this website should be interpreted as a guarantee or representation that VivoSim will achieve any particular financial, commercial, scientific, regulatory, or operational result.
References to market opportunities, revenue targets, potential applications, technology performance, customer opportunities, regulatory developments, or future growth should be understood in the context in which they are presented and, where applicable, as company estimates or forward-looking statements.
Past performance, scientific results, historical examples, or previously reported developments should not be interpreted as an indication of future performance.
Independent Evaluation
Investing in securities involves risk, including the potential loss of principal.
Before making any investment decision regarding VivoSim Inc. (NASDAQ: VIVS), investors should review the Company’s publicly available filings, financial statements, risk factors, press releases, and other disclosures and perform their own independent analysis.
VivoSim Inc. (NASDAQ: VIVS) and its securities should be evaluated based on the Company’s publicly available information and an investor’s individual circumstances, objectives, and risk tolerance.